Enantia at Future Cannabis Strategies Europe 2020

Enantia at Future Cannabis Strategies Europe 2020

News

Home > News > Enantia celebrates its 15th anniversary
Enantiacelebratesits15thanniversary

Enantia at Future Cannabis Strategies Europe 2020

January 17th, 2019

Our CEO Dr. Joan Feixas will be attending the Future Cannabis Strategies Europe 2020, taking place in Royal Lancaster London on the 29th and 30th of January, 2020.

During the event, we will be discussing with key partners and customers about our Cannabinoids Cocrystal Platform, which enables the manufacturing of a wide range of cannabinoids, both from natural and synthetic origin.

As part of this platform, Enantia is already developing commercial batches of API grade cGMP Cannabidiol (CBD), along with minor cannabinoids such as Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabichromene (CBC) and Cannabinol (CBN).

If you are interested in our very high-quality cannabinoids, or if you are looking for a cost-effective purification technology for your cannabis extracts, do not hesitate to contact us to organize a meeting.

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

News

Home > News > Barcelona Science Park’s 20th anniversary

BarcelonaScienceParks20thanniversary

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

The Journal of Medicinal Chemistry has recently published some of the results obtained in our Medicinal Chemistry collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s RD activity to develop new, potent and safer analgesics.

The chemistry work, which was carried out by Enantia’s Medicinal Chemistry team led by Dr. Marina Virgili, started with the design of the spirocyclic morpholino-piperidine core using rational drug design strategies. The efficient synthetic approach developed, allowed then for the rapid preparation of analogues with diversification in several positions of the scaffold, rendering the promising Lead described in this paper. The subsequent Lead Optimization program led to the discovery of a clinical candidate, whose identification will be reported soon.

Enantia has a long track record in Medicinal Chemistry services to the pharmaceutical industry, with more than 20 patents related to this activity, which includes the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity.

In addition to conventional MedChem activities such as Hit-to-Lead and Lead Optimization programs, Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) interpretation, Enantia can also collaborate in the early stages of the drug development process by preparing cold labelled compounds and metabolites of a given candidate, as well as by identifying its best solid form in our Solid State department.

You can read the full paper here.

Merry Christmas and prosperous 2020!

Merry Christmas and prosperous 2020!

News

Home > News > Season’s greetings 2019
merrychrismasenantia

Merry Christmas and prosperous 2020!

December 17th, 2019

Special greetings at Christmas time to express our sincere thanks to everyone that has placed their confidence and loyalty to Enantia and has made this successful year possible.

Thanks to all our customers, employees, and suppliers, we wish you merry Christmas and a happy and prosperous 2020!

 

Enantia supports an environmental-friendly paper-free holiday season.

Biofit 2019

Biofit 2019

News

Home > News > Enantia at Biofit 2018
EnantiaatBiofit2018

Enantia at Biofit 2019

December 13th, 2019

 

On December 10th and 11th Marseille hosted the 8th Biofit event for big pharma, biotech companies, CROs and public research institutes.

On this edition, Enantia was selected to participate in the Service pitch session, in which we presented our state-of-the-art cocrystallization technology that enables selective, scalable and affordable purification processes of substances in complex mixtures.

We had the chance to strength former collaborations and to foster new networks. Thanks to everyone who came along.

Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019

News

Home > News > Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia CPHI 2019

Enantia at the 30th edition of the CPhI Worldwide 2019

November 19th, 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019 event that took place in Frankfurt (Germany) from the 5th to the 7th of November.

Thanks to everyone for the interesting meetings.

We had the chance to discuss not only our services in chemical discovery and development, but also our cannabinoids cocrystal platform and the minor cannabinoids that we offer (CBDV, CBG, CBC, CBN).

We hope to meet you all very soon.